导管原位癌局部治疗是否存在替代策略？
Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
作者信息
Rosso Kelly J, Weiss Anna, Thompson Alastair M
机构信息
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, FCT7.6092, Unit 1434, 1400 Pressler Street, Houston, Texas 77030-4008, USA.
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, FCT7.6092, Unit 1434, 1400 Pressler Street, Houston, Texas 77030-4008, USA.
出版信息
Surg Oncol Clin N Am. 2018 Jan;27(1):69-80. doi: 10.1016/j.soc.2017.08.002.
The management of ductal carcinoma in situ (DCIS) has traditionally followed the evidence base for invasive breast cancer using surgery, radiation therapy, and drug therapy to remove the DCIS from the breast and reduce the risk of recurrence for both DCIS and invasive breast cancer. Because of concerns regarding the overtreatment of DCIS, randomized controlled trials have been established to test the outcomes (invasive breast cancer outcomes and patient-reported outcome measures) of active surveillance compared with guideline-concordant care for low-risk (for progression) DCIS. These strategies are undergoing rigorous evaluation to evaluate alternatives to the current management of DCIS.
导管原位癌（DCIS）的治疗传统上遵循浸润性乳腺癌的循证医学依据，采用手术、放射治疗和药物治疗来清除乳腺中的DCIS，并降低DCIS和浸润性乳腺癌的复发风险。由于担心对DCIS的过度治疗，已开展随机对照试验，以测试与低风险（进展风险）DCIS的指南一致治疗相比，主动监测的结果（浸润性乳腺癌结果和患者报告的结局指标）。这些策略正在接受严格评估，以评估DCIS当前治疗方法的替代方案。
Zotero 插件